论文部分内容阅读
连续性肾脏替代治疗（CRRT）已从单纯的肾脏替代发展为多器官支持手段，广泛应用于重症监护病房（ICU）。2019新型冠状病毒肺炎（简称新冠肺炎）暴发以来，多个诊疗指南或专家建议相继出台，提及发生急性肾损伤（AKI）或过激的炎症反应时可采用CRRT治疗。但无论从病毒传染的病理生理，还是传染病防控等方面，新冠肺炎患者的CRRT都与常规CRRT的开展有很大不同。本文从治疗安全性和适用性、适应证和时机、临床操作、抗凝管理、液体管理及传染病防控等方面，阐述新冠肺炎患者CRRT与常规CRRT的异同。“,”Continuous renal replacement therapy (CRRT) has become an effective multiple organ support therapy instead of single renal replacement as initially expected, and it is widely used in intensive care unit (ICU). After the outbreak of coronavirus disease 2019 (COVID-19), a series of expert recommendation or consensus have been developed to diagnose and treat the disease, including CRRT in acute kidney injury (AKI) and hyper inflammatory response. However, CRRT in COVID-19 is extraordinarily different from regular one due to different pathophysiology and infectious clinical scenarios. Accordingly, the paper aims to elaborate the similarities and differences between CRRT in COVID-19 and routine treatment in terms of safety and accessibility, indications and timing, clinical operation, anticoagulation, fluid management, prevention and control of infectious diseases, etc.